e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): May 5, 2009
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
         
         
Delaware   1-11397   33-0628076
(State or other jurisdiction of   (Commission File Number)   (I.R.S Employer
incorporation or organization)       Identification No.)
One Enterprise
Aliso Viejo, California 92656

(Address of principal executive offices) (Zip Code)
(949) 461-6000
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
 
 
 

 


TABLE OF CONTENTS

Item 2.02 Results of Operations and Financial Condition
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
INDEX TO EXHIBITS
EX-99.1


Table of Contents

Item 2.02 Results of Operations and Financial Condition
     On May 5, 2009, Valeant Pharmaceuticals International issued a press release announcing results of operations for the quarter ended March 31, 2009 and certain other financial information as of and for the quarter ended March 31, 2009. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.
     The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
     
99.1
  Press release dated May 5, 2009.

 


Table of Contents

SIGNATURES
          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
       
VALEANT PHARMACEUTICALS INTERNATIONAL
 
 
Date: May 5, 2009 By:   /s/ Peter J. Blott    
    Peter J. Blott   
    Executive Vice President
and Chief Financial Officer  
 
 
 

 


Table of Contents

INDEX TO EXHIBITS
     
99.1
  Press release dated May 5, 2009.